Key clinical point: Avoidance of severe cognitive impairment guided parent and physician choices more than any other late-life risk associated with cancer treatment.

Major finding: Parents were more likely to choose a treatment associated with no or mild neurocognitive impairment, compared with one that caused severe impairment (odds ratio, 2.83 for no impairment vs. severe impairment; P less than .001), in exchange for a 10% higher risk of treatment failure.

Study details: A discrete choice experiment survey to which 95 parents and 41 physicians responded at a single cancer treatment center.

Disclosures: Dr. Greenzang and colleagues’ study was funded by the National Institutes of Health and an Agency for Healthcare Research and Quality grant. The investigators declared no relevant financial disclosures.